Could it be that we have the opportunity to spot the early stages of ovarian cancer?
On a yearly basis, 14,000 women die from ovarian cancer, out of the 20,000 women that are diagnosed with it. Because there is no standard way of detecting change or abnormal growths in the ovaries, detection of ovarian cancer happens later and survival rates drop to 30%.
The latest results published in Cancer journal, found that tracking blood proteins over time, rather than with one blood test, was more accurate in predicting ovarian cancer. For 11 years, scientists at MD Anderson Cancer Center have been studying the blood protein called CA125 in women, post-menopause. They discovered that changes in this blood protein act as a biomarker for tumors.
Currently, another test is being conducted in the UK on 200,000 women to determine if tracking these changes in the blood protein, over time, will serve as a better test and manner of practice for cancer prevention. If the changing protein levels of CA125 in the blood are proven to reflect a risk in cancer, we will be able to catch ovarian cancer in its early stages, where preventative action such as medication, chemotherapy, and radiation are much more effective.